Bioblast Pharma (ORPN) Stock Price, News & Analysis

Company Overview

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Key Stats

• Today's Range: $1.10 to $1.19
• 50-Day Range: $11.50 to $28.49
• 52-Week Range: $6.16 to $30.00
• Volume: 86,085 shs
• Average Volume: N/A
• Market Capitalization: $478,800.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ORPN Stock Analysis - Frequently Asked Questions

When did Bioblast Pharma's stock split?

Shares of Bioblast Pharma reverse split before market open on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Bioblast Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), SELLAS Life Sciences Group (SLS), Immunomedics (IMMU), Athersys (ATHX), ContraFect (CFRX) and Corbus Pharmaceuticals (CRBP).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ORPN
• CUSIP: N/A
• CIK: 1596812
• Web: bioblastpharma.com
• Phone: (722) 670-8072
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.56 per share
• Price / Book: 0.15

Miscellaneous

• Outstanding Shares: 420,000
• Free Float: N/A
• Market Cap: $478,800.00
• Optionable: Not Optionable
• Beta: 1.41